

ANIKA THERAPEUTICS INC  
Form 8-K  
April 28, 2005

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **April 27, 2005**

**Anika Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other jurisdiction of  
incorporation or organization)

**000-21326**  
Commission file number

**04-314-5961**  
(I.R.S. Employer  
Identification No.)

**160 New Boston Street, Woburn, MA 01801**  
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: **781-932-6616**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Edgar Filing: ANIKA THERAPEUTICS INC - Form 8-K

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition.

On April 27, 2005, Anika Therapeutics, Inc. issued a press release announcing its financial results for the first quarter of 2005. The full text of the press release is furnished as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1                      Press Release of Anika Therapeutics, Inc. dated April 27, 2005.

[Remainder of page left blank intentionally]

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be filed on its behalf by the undersigned hereunto duly authorized.

Anika Therapeutics, Inc.

Dated: April 27, 2005

By: /s/ Charles H. Sherwood  
Charles H. Sherwood, Ph.D.  
President and Chief Executive Officer

Exhibit Index

99.1 Press Release of Anika Therapeutics, Inc. dated April 27, 2005.